Dicerna Pharmaceuticals Inc (DRNA) Scheduled to Post Quarterly Earnings on Wednesday
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is set to release its earnings data after the market closes on Wednesday, March 22nd. Analysts expect Dicerna Pharmaceuticals to post earnings of ($0.73) per share for the quarter.
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) opened at 2.86 on Tuesday. The company’s market cap is $59.35 million. The firm’s 50-day moving average price is $2.78 and its 200-day moving average price is $3.31. Dicerna Pharmaceuticals Inc has a 12-month low of $2.42 and a 12-month high of $6.10.
Your IP Address:
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/dicerna-pharmaceuticals-inc-drna-scheduled-to-post-quarterly-earnings-on-wednesday.html
An institutional investor recently raised its position in Dicerna Pharmaceuticals stock. Dimensional Fund Advisors LP boosted its stake in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 7.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,978 shares of the biopharmaceutical company’s stock after buying an additional 2,705 shares during the period. Dimensional Fund Advisors LP owned about 0.18% of Dicerna Pharmaceuticals worth $106,000 at the end of the most recent reporting period. 58.56% of the stock is owned by institutional investors.
A number of brokerages have recently commented on DRNA. Leerink Swann reiterated a “mkt perform” rating on shares of Dicerna Pharmaceuticals in a report on Wednesday, February 1st. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 17th. Finally, HC Wainwright began coverage on shares of Dicerna Pharmaceuticals in a report on Monday, December 12th. They set a “buy” rating and a $7.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $8.21.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.